Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TACR2 | P21452 | 2/20 | 0.32 |
| ▸ | TACR1 | P25103 | 2/20 | 0.32 |
| ▸ | FAP | Q12884 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL870538 | 1.00 | CYP1A2 (0.33) | CYP1A2CYP2D6CYP2C9CYP2C19TACR2 | |
| SCHEMBL870536 | 1.00 | CYP1A2 (0.33) | CYP1A2CYP2D6CYP2C9CYP2C19TACR2 | |
| SCHEMBL871006 | 0.95 | FAP (0.31) | FAP | |
| SCHEMBL871004 | 0.95 | FAP (0.31) | FAP | |
| SCHEMBL871005 | 0.95 | FAP (0.31) | FAP | |
| SCHEMBL872705 | 0.93 | — | — | |
| SCHEMBL872706 | 0.93 | — | — | |
| SCHEMBL872704 | 0.93 | — | — | |
| SCHEMBL870146 | 0.92 | CYP1A2 (0.33) | CYP1A2CYP2D6CYP2C9CYP2C19TACR2 | |
| SCHEMBL870147 | 0.92 | CYP1A2 (0.33) | CYP1A2CYP2D6CYP2C9CYP2C19TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404649-B2 | Isoxazoline oximes as antiparasitic agents | AH USA 42 LLC (US) | 2013-03-26 | — | — | US | claimed |
| US-20120077765-A1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | PFIZER INC. (US) | 2012-03-29 | — | — | US | claimed |
| EP-2619189-B1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | ZOETIS SERVICES LLC (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-2619189-A1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | Zoetis LLC (US) | 2013-07-31 | — | — | EP | disclosed |
| US-8404649-B2 | Isoxazoline oximes as antiparasitic agents | AH USA 42 LLC (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120077765-A1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | PFIZER INC. (US) | 2012-03-29 | — | — | US | disclosed |
| WO-2012038851-A1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | PFIZER INC. (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077765-A1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | CYP1A2, CYP3A7, CYP2E1 | CYP1A2 1/4885CYP2D6 35/4885CYP2C9 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.